Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.72 |
| ▸ | EED | O75530 | 10/20 | 0.72 |
| ▸ | SUZ12 | Q15022 | 10/20 | 0.72 |
| ▸ | EZH1 | Q92800 | 6/20 | 0.72 |
| ▸ | RBBP4 | Q09028 | 5/20 | 0.72 |
| ▸ | AEBP2 | Q6ZN18 | 4/20 | 0.72 |
| ▸ | RBBP7 | Q16576 | 3/20 | 0.72 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.60 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15391460 | 0.93 | EZH2 (0.69) | EZH2EEDSUZ12EZH1RBBP4 | |
| SCHEMBL15391128 | 0.92 | EZH2 (0.72) | EZH2EEDSUZ12EZH1RBBP4 | |
| SCHEMBL15391422 | 0.86 | EZH2 (0.71) | EZH2EEDSUZ12EZH1RBBP4 | |
| SCHEMBL2593962 | 0.84 | EZH2 (0.80) | EZH2EEDSUZ12EZH1RBBP4 | |
| SCHEMBL16115012 | 0.84 | EZH2 (0.71) | EZH2EEDSUZ12EZH1RBBP4 | |
| SCHEMBL2590353 | 0.84 | EZH2 (1.00) | EZH2EEDSUZ12EZH1RBBP4 | |
| SCHEMBL29397460 | 0.84 | EZH2 (1.00) | EZH2EEDSUZ12EZH1RBBP4 | |
| SCHEMBL2595868 | 0.84 | EZH2 (1.00) | EZH2EEDSUZ12EZH1RBBP4 | |
| SCHEMBL17026256 | 0.84 | EZH2 (0.66) | EZH2EEDSUZ12EZH1RBBP4 | |
| SCHEMBL29351554 | 0.84 | EZH2 (1.00) | EZH2EEDSUZ12EZH1RBBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10478426-B2 | Enhancer of Zeste Homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-11-19 | — | — | US | disclosed |
| US-10478426-B2 | Enhancer of Zeste Homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-11-19 | — | — | US | disclosed |
| US-20180207144-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2018-07-26 | — | — | US | disclosed |
| US-20180207144-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2018-07-26 | — | — | US | disclosed |
| US-20180207144-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2018-07-26 | — | — | US | disclosed |
| US-9956210-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2018-05-01 | — | — | US | disclosed |
| US-9956210-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2018-05-01 | — | — | US | disclosed |
| US-9956210-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170095461-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2017-04-06 | — | — | US | disclosed |
| US-20170095461-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2017-04-06 | — | — | US | disclosed |
| US-20170095461-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2017-04-06 | — | — | US | disclosed |
| US-9562041-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562041-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562041-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-02-07 | — | — | US | disclosed |
| US-20150126522-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126522-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126522-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207144-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, EZH1, BMI1 | EZH2 1/4885EED 6/4885SUZ12 4/4885 |
| US-20170095461-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, EZH1, BMI1 | EZH2 1/4885EED 6/4885SUZ12 4/4885 |
| US-10478426-B2 | Enhancer of Zeste Homolog 2 inhibitors | EZH2, EZH1, BMI1 | EZH2 1/4885EED 6/4885SUZ12 4/4885 |
| US-20150126522-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, EZH1, BMI1 | EZH2 1/4885EED 6/4885SUZ12 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.